查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1853516

帶狀皰疹疫苗市場按疫苗類型、年齡層、最終用戶、通路和劑量分類－2025-2032年全球預測

Shingles Vaccine Market by Vaccine Type, Age Group, End User, Distribution Channel, Dosage - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，帶狀皰疹疫苗市場規模將達到 35.6 億美元，複合年成長率為 8.36%。

關鍵市場統計數據
基準年2024年 18.7億美元
預計年份：2025年 20.2億美元
預測年份 2032 35.6億美元
複合年成長率（%） 8.36%

全面了解影響帶狀皰疹疫苗策略的臨床、商業性和政策因素，以及這些因素對整個價值鏈相關人員的影響。

帶狀皰疹是由水痘-帶狀皰疹病毒重新運作引起的，由於其發病率隨年齡成長而增加，且伴隨嚴重的併發症，如帶狀皰疹後遺症神經痛，因此仍然是老年人群中一個重要的公共衛生問題。疫苗技術的進步正在重塑預防策略，而支付方和分銷管道的變化正在影響疫苗的可及性和接種率。本執行摘要概述了重塑帶狀皰疹疫苗格局的最重要臨床、商業和政策趨勢，並重點闡述了這些趨勢對研發、生產、分銷和患者護理等各個環節的相關人員的影響。

近年來，重組疫苗平台的出現為傳統的活病毒疫苗製劑提供了更有效的替代方案，改變了臨床建議和免疫接種途徑。同時，人口老化帶來的人口壓力以及對成人免疫接種計畫日益重視，也重新激發了公共衛生機構和私人支付者的關注。因此，生產者、醫療服務提供者和經銷商正在重新評估其供應策略、服務模式和溝通方式，以最大限度地提高免疫接種覆蓋率，並最大限度地減少可預防疾病的負擔。

本導言為報告後續分析奠定了基礎，包括不斷變化的行業格局、累積的政策影響、基於細分的需求促進因素、區域細微差別、競爭格局、對行業領導者的建議行動以及調查方法，旨在組裝一個連貫的、以決策為導向的敘述，以支持在日益複雜的環境中進行戰略規劃和營運執行。

本文詳細描述了影響帶狀皰疹疫苗接種、採購方式以及整個醫療保健生態系統中相關人員期望的多維度顛覆性因素。

帶狀皰疹疫苗領域正經歷一系列變革性變化，其影響範圍不僅限於產品性能，還涵蓋分銷、支付方參與和患者期望等多個方面。包括改進的重組抗原平台和佐劑系統在內的技術進步，提高了疫苗效力標準，改變了臨床指南，並促使醫療系統和臨床醫生重新評估成人疫苗通訊協定。同時，低溫運輸物流和數位化分銷管道的進步，在擴大疫苗覆蓋範圍的同時，也為庫存管理和供應商選擇帶來了新的考量。

支付方正轉向基於價值的採購和與績效掛鉤的合約模式，獎勵生產者證明其產品具有長期的臨床和經濟效益。這種以結果為導向的報銷趨勢正在推動對真實世界證據的生成和上市後監測的投入增加。同時，監管機構也正在完善核准和標籤流程，以更好地反映不同年齡層的風險獲益比，進而影響國家免疫技術諮詢小組和臨床學會的建議。

患者的期望和醫療服務提供者的工作流程也在不斷變化。同時，初級保健和專科診所擴大將疫苗接種納入慢性病常規管理。此外，數位藥局和電子商務平台在藥品取得方面發揮越來越重要的作用，這加速了新型分銷模式的採用，也因此需要圍繞低溫運輸保障和用藥依從性支持建立新的管治。這些變化共同重塑了整個生態系統的競爭優勢和營運重點。

深入分析關稅主導的貿易動態如何再形成帶狀皰疹疫苗供應鏈決策、採購彈性策略和商業合約方式

關稅和貿易措施等政策調整將對整個醫藥供應鏈產生下游影響，而美國預計2025年實施的關稅政策正迫使相關人員評估其營運的韌性。製造商和經銷商正在重新審視關鍵原料、佐劑和管瓶的籌資策略，以降低進口成本上升和海關延誤的風險。為此，採購團隊正在拓展供應商基礎，加快區域製造商的資格認證，並談判包含價格保護條款的長期契約，以確保供應的連續性。

物流合作夥伴和低溫運輸供應商也積極應對潛在的成本變化，他們透過最佳化路線、整合貨物以及探索近岸外包機會來降低關稅相關風險。雖然這些營運調整可能會導致某些投入品的前置作業時間延長，但也促使企業加大對國內灌裝和包裝能力以及冷藏基礎設施的投資。由於供應負責人會根據合約承諾和預期需求來確定物資分配的優先順序，臨床醫生和醫療系統應預料到採購順序可能會出現波動。

從商業性角度來看，進口關稅的上漲可能會對定價策略、利潤結構以及與支付方和經銷商的合約方式造成壓力。製造商可能會尋求跨通路差異化定價，或將依從性支援和分​​析等服務打包銷售，以維持其整體價值提案。監管和政策相關人員可能會加強合作，加快核准替代供應商，並確保國家疫苗接種工作在貿易中斷的情況下保持韌性。總而言之，這些累積影響凸顯了積極主動的供應鏈管治、基於情境的規劃以及加強公私合營的重要性。

主導了解疫苗類型、年齡層、最終用戶、分銷管道和接種方式如何相互作用，從而影響疫苗接種率和供應。

對帶狀皰疹疫苗市場進行細分，有助於了解產品、人群、醫療機構、分銷模式和接種方案如何相互作用，從而影響疫苗的推廣路徑和服務提供模式。疫苗類型可區分重組帶狀皰疹疫苗和減毒帶狀皰疹疫苗。重組疫苗在老年族群中療效較高，並正在影響臨床指引；而減毒帶狀皰疹疫苗在某些臨床環境中仍適用。評估產品系列的決策者必須考慮這些療效和安全性差異，以及影響下游物流的儲存和處理要求。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 重組佐劑帶狀皰疹疫苗在50歲及以上成年人的全球普及率迅速提高
  • 將帶狀皰疹疫苗接種納入全國成人常規免疫計劃
  • 增加對採用新型mRNA技術的下一代帶狀皰疹候選疫苗的投資
  • 重點關注新興市場的疫苗接種計劃，以縮小老年人帶狀皰疹疫苗接種方面的差距
  • 加強消費者教育宣傳活動，重點在於新型帶狀皰疹疫苗的長期有效性與安全性
  • 新興企業公司與大型製藥公司夥伴關係研究，共同開發下一代帶狀皰疹免疫原。

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 帶狀皰疹疫苗市場（依疫苗類型分類）

  • 重組帶狀皰疹疫苗
  • 帶狀皰疹活疫苗

9. 按年齡層別分類的帶狀皰疹疫苗市場

  • 50至59歲
  • 60至69歲
  • 70歲或以上

第10章 帶狀皰疹疫苗市場（以最終用戶分類）

  • 診所
    • 社區診所
    • 私人診所
  • 醫院
    • 綜合醫院
    • 專科醫院

第11章 帶狀皰疹疫苗市場（依通路分類）

  • 醫院藥房
  • 網路藥局
    • 數位藥房
    • 電商平台
  • 零售藥局
    • 連鎖藥局
    • 獨立藥房

12. 帶狀皰疹疫苗市場（依劑量分類）

  • 多劑量
  • 單一劑量

第13章 帶狀皰疹疫苗市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 帶狀皰疹疫苗市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國帶狀皰疹疫苗市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • GlaxoSmithKline plc
    • Merck & Co., Inc.
    • SK chemicals
    • GeneOne Life Science
    • CanSinoBIO
    • Moderna, Inc.
    • Chengdu Institute of Biological Products Co., Ltd.
    • Beijing Institute of Biological Products Co., Ltd.
    • Yuxi Walvax Biotechnology Co., Ltd.
Product Code: MRR-563BF1FCEEC2

The Shingles Vaccine Market is projected to grow by USD 3.56 billion at a CAGR of 8.36% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.87 billion
Estimated Year [2025] USD 2.02 billion
Forecast Year [2032] USD 3.56 billion
CAGR (%) 8.36%

Comprehensive orientation to the clinical, commercial, and policy forces shaping shingles vaccine strategy with implications for stakeholders across the value chain

Shingles, caused by reactivation of varicella-zoster virus, remains a significant public health concern for older adults due to rising incidence with advancing age and the debilitating complications associated with postherpetic neuralgia. Advances in vaccine technology have reshaped prevention strategies, while evolving payer landscapes and distribution shifts are influencing access and uptake. This executive summary consolidates the most salient clinical, commercial, and policy trends that are reshaping the shingles vaccine environment and highlights the implications for stakeholders across development, manufacturing, distribution, and patient care delivery.

In recent years, recombinant vaccine platforms have introduced higher-efficacy alternatives to older live-attenuated formulations, altering clinical recommendations and immunization pathways. At the same time, demographic pressures from aging populations and intensified focus on adult immunization programs are generating renewed attention among public health authorities and private payers. As a result, manufacturers, providers, and distributors are reassessing supply strategies, service delivery models, and communication approaches to maximize coverage and minimize preventable disease burden.

This introduction frames the report's subsequent analysis, which explores transformative shifts in the landscape, cumulative policy impacts, segmentation-driven demand drivers, regional nuances, competitive positioning, recommended actions for industry leaders, and the research methodology underpinning the findings. The intent is to present a coherent, decision-oriented narrative that supports strategic planning and operational execution in an increasingly complex environment.

Detailed exposition of the multi-dimensional disruptive forces altering shingles vaccine adoption, procurement approaches, and stakeholder expectations across health ecosystems

The shingles vaccine landscape is experiencing a set of transformative shifts that extend beyond product performance and into distribution, payer engagement, and patient expectations. Technological advances, including improved recombinant antigen platforms and adjuvant systems, have elevated efficacy benchmarks and altered clinical guidance, prompting health systems and clinicians to reevaluate adult immunization protocols. Concurrently, advances in cold-chain logistics and digital distribution channels are enabling broader access while introducing new considerations for inventory management and supplier selection.

Payer dynamics are shifting toward value-based procurement and performance-linked contracting, which is incentivizing manufacturers to demonstrate long-term clinical and economic benefits. This emphasis on outcome-oriented reimbursement is driving increased investment in real-world evidence generation and post-marketing surveillance. In parallel, regulatory authorities are refining approval and labeling pathways to better reflect age-stratified risk-benefit profiles, which in turn affects recommendations from national immunization technical advisory groups and clinical societies.

Patient expectations and provider workflows are also evolving. Older adults are increasingly informed about vaccine options and seek clear guidance on comparative efficacy and safety, while primary care settings and specialist clinics are integrating vaccination into routine chronic disease management visits. Finally, the growing role of digital pharmacies and e-commerce platforms in medication access is accelerating the adoption of novel distribution models, necessitating new governance around cold-chain assurance and adherence support. Together, these shifts are redefining competitive advantage and operational priorities across the ecosystem.

In-depth analysis of how tariff-driven trade dynamics are reshaping supply chain decisions, procurement resilience strategies, and commercial contracting approaches for shingles vaccines

Policy adjustments such as tariffs and trade measures can create downstream effects across pharmaceutical supply chains, and anticipated tariff actions in the United States in 2025 have prompted stakeholders to assess operational resiliency. Manufacturers and distributors are re-evaluating sourcing strategies for critical raw materials, adjuvants, and vials to mitigate exposure to increased import costs and potential customs-related delays. In response, procurement teams are diversifying supplier bases, accelerating qualification of regional manufacturers, and negotiating longer-term contracts with price protection clauses to preserve continuity of supply.

Logistics partners and cold-chain providers are also adapting to potential cost shifts by optimizing routing, consolidating shipments, and exploring nearshoring opportunities to reduce tariff-related risk. These operational adjustments may increase lead times for certain inputs while prompting investment in domestic fill-and-finish capacity and additional cold-storage infrastructure. Clinicians and health systems should expect potential variations in procurement cadence as supply planners prioritize allocations based on contractual commitments and anticipated demand.

From a commercial perspective, increased import duties can pressure pricing strategies, margin structures, and contracting approaches with payers and distributors. Manufacturers may pursue differentiated pricing across channels or seek to bundle services-such as adherence support or analytics-to sustain overall value propositions. Regulatory and policy stakeholders are likely to intensify collaboration to expedite approvals for alternative suppliers and to ensure that national immunization efforts remain resilient in the face of trade-driven disruptions. Overall, the cumulative effect underscores the importance of proactive supply chain governance, scenario-based planning, and strengthened public-private coordination.

Strategic segmentation-driven insights that decode how vaccine type, age cohorts, end users, distribution channels, and dosing formats interact to influence adoption and delivery

Segmentation of the shingles vaccine landscape illuminates how product, demographic, care setting, distribution patterns, and dosing regimens interact to shape adoption pathways and service delivery models. Based on vaccine type, the environment distinguishes between recombinant zoster vaccine formulations, which have influenced clinical guidelines through higher observed efficacy in older cohorts, and live-attenuated zoster vaccine options that retain relevance in specific clinical circumstances. Decision-makers evaluating product portfolios must consider these efficacy and safety differentials alongside storage and handling requirements that affect downstream logistics.

Based on age group, demand drivers and clinical priorities vary across those aged 50 to 59 years, 60 to 69 years, and those 70 years and above. Younger older adults often present opportunities for proactive preventive outreach and workplace-based vaccination programs, whereas patients aged 70 and above frequently require tailored messaging around comorbidity management and safety signals. Providers must therefore align clinical communications and outreach workflows to the age-stratified risk-benefit calculus in order to improve uptake across cohorts.

Based on end user, delivery pathways bifurcate between clinics and hospitals, with clinics further differentiated into community clinics and private clinics and hospitals further categorized into general hospitals and specialty hospitals. Community clinics often serve as primary access points for preventive care with strong ties to local public health initiatives, while private clinics frequently emphasize patient convenience and bundled preventive services. General hospitals manage large-scale procurement and account for inpatient vaccination needs, whereas specialty hospitals may target vaccination for high-risk patient populations undergoing specific therapies. Each end-user segment requires distinct engagement strategies related to inventory management, clinician education, and reimbursement navigation.

Based on distribution channel, access is facilitated through hospital pharmacies, online pharmacies, and retail pharmacies, with online pharmacies further consisting of digital pharmacies and e-commerce platforms and retail pharmacies including chain pharmacies and independent pharmacies. Hospital pharmacies play a central role in institutional procurement and cold-chain stewardship, while online channels enable convenience and direct-to-consumer fulfillment that must be supported by robust temperature control and authentication protocols. Chain retail pharmacies offer scale and standardized vaccination services, whereas independent pharmacies provide localized patient counseling and flexible scheduling. Channel strategies must therefore integrate service design, cold-chain verification, and digital engagement to ensure both accessibility and adherence.

Based on dosage, delivery considerations span multi-dose and single-dose presentations. Multi-dose presentations can improve supply efficiency in high-volume settings but require stringent cold-chain and multi-dose vial handling procedures, whereas single-dose presentations support point-of-care convenience and reduce wastage in lower-volume environments. Manufacturers and providers should weigh dosing format decisions against clinic throughput, storage constraints, and patient flow dynamics to optimize both clinical outcomes and operational performance.

Comparative regional perspectives that reveal how payer dynamics, infrastructure, and demographic pressures drive differentiated adoption and access strategies across global theaters

Regional dynamics shape both the operational realities and strategic imperatives for stakeholders across the shingles vaccine value chain. In the Americas, public and private payers are increasingly focused on adult immunization schedules and value demonstration, which has accelerated investments in community outreach and integrated care pathways to improve coverage among older adults. Health systems in major markets are leveraging electronic health records and immunization registries to close care gaps, while distribution networks emphasize refrigerated logistics and chain pharmacy partnerships to maximize access.

In Europe, Middle East & Africa, regulatory heterogeneity and variable health system maturity produce a mosaic of adoption scenarios. High-income countries within the region generally align their clinical guidance with emerging efficacy evidence, while middle- and lower-income countries prioritize cost-effective procurement and targeted risk-group immunization. Cold-chain infrastructure variability in certain markets underscores the importance of adaptable product formats and decentralized storage solutions. Cross-border procurement mechanisms and regional regulatory harmonization efforts are increasingly relevant for manufacturers considering supply commitments and pricing strategies.

In the Asia-Pacific region, demographic shifts and expanding healthcare infrastructure are driving heightened demand for adult immunization services. Many markets are scaling up primary care capability and digital health platforms that can facilitate vaccine awareness and appointment scheduling. Local manufacturing capacity and strategic partnerships are likewise being prioritized to enhance supply security and shorten lead times. Across these regional contexts, tailored commercialization models that account for payer structure, distribution maturity, and public health priorities will be essential to achieving sustainable adoption and programmatic impact.

Holistic competitive intelligence highlighting how clinical evidence, operational resilience, and strategic partnerships define leadership in the shingles vaccine landscape

Competitive positioning in the shingles vaccine arena now rests on an integrated set of capabilities that extend beyond clinical differentiation to include supply chain agility, evidence generation, and multi-channel commercial excellence. Leading organizations are investing in post-authorization studies and real-world evidence programs to substantiate long-term effectiveness and to support contracting discussions with payers and health systems. At the same time, operational excellence in cold-chain logistics, fill-and-finish capacity, and supplier diversification has become a strategic priority to mitigate tariff and trade-related risks.

Strategic alliances and manufacturing partnerships are increasingly common as companies seek to broaden geographic reach while containing capital expenditure. Collaborative approaches to distribution-combining hospital procurement networks with retail pharmacy programs and digital fulfillment-are enabling more seamless patient journeys. Marketing efforts are focusing on clear, age-tailored clinical messaging and on clinician-facing education to ensure that vaccine options are integrated into routine care for older adults. Additionally, firms that develop robust adherence and patient-support services are better positioned to demonstrate value to payers and providers under outcome-oriented contracting models.

Intellectual property stewardship, regulatory preparedness, and the capacity to scale commercial operations rapidly during periods of heightened demand further distinguish market leaders. Organizations that align clinical evidence, operational resilience, and stakeholder engagement are most likely to sustain competitive advantage in a dynamic landscape where product efficacy, distribution integrity, and payer alignment converge to determine adoption outcomes.

Action-oriented recommendations that align evidence generation, supply resilience, omnichannel distribution, and stakeholder collaboration to accelerate vaccine access and uptake

Industry leaders should prioritize a set of pragmatic, high-impact actions to navigate the evolving shingles vaccine environment and to capitalize on emerging opportunities. First, organizations must invest in granular real-world evidence generation that demonstrates comparative effectiveness across age bands and clinical subgroups, enabling more compelling value propositions in payer negotiations and clinician adoption discussions. Second, strengthening supply chain resilience through supplier diversification, regional manufacturing partnerships, and validated cold-chain contingency plans will reduce exposure to trade and tariff volatility.

Third, manufacturers and distributors should advance omnichannel distribution strategies that harmonize hospital procurement, retail pharmacy scale, and secure online fulfillment, while ensuring rigorous cold-chain verification and patient adherence support. Fourth, tailored engagement programs for different end users-community clinics, private clinics, general hospitals, and specialty hospitals-will improve uptake by aligning service delivery models and inventory management to specific operational needs. Fifth, commercial teams should develop flexible contracting frameworks and bundled service offerings that reflect payer preferences for outcomes and long-term value, thereby facilitating access in both public and private settings.

Finally, cross-sector collaboration with public health authorities, patient advocacy groups, and clinical societies will amplify outreach efforts and establish clearer adult immunization pathways. By combining evidence generation, operational readiness, channel optimization, and stakeholder alignment, industry leaders can enhance vaccine accessibility and deliver measurable public health impact.

Transparent mixed-methods research approach that integrates expert interviews, regulatory synthesis, and scenario analysis to produce actionable, validated insights for decision-makers

This analysis draws on a mixed-methods research approach designed to integrate primary stakeholder insights with rigorous secondary synthesis and validation. The core methodology combined in-depth interviews with clinical experts, procurement leaders, and distribution partners alongside structured data extraction from public regulatory communications, clinical literature, and policy statements. Interviews were conducted across a range of care settings and regions to capture the operational diversity influencing vaccine delivery and to triangulate emerging themes around adoption barriers and enablers.

Complementing qualitative insights, the research incorporated scenario-based supply chain analysis to assess resilience considerations under different trade and policy conditions. Key assumptions were tested through sensitivity checks and cross-validated with logistics and manufacturing specialists to ensure feasibility and practical relevance. The approach prioritized transparency of sources, explicit documentation of analytic steps, and iterative validation with subject-matter experts to reduce bias and increase applicability for decision-makers.

Ethical considerations were observed in all primary research activities, and data handling adhered to relevant confidentiality and privacy standards. Where applicable, clinical findings referenced peer-reviewed evidence and regulatory guidance to contextualize recommendations. The resulting synthesis emphasizes actionable intelligence and pragmatic pathways for implementation, intended to inform strategic planning rather than provide normative policy prescriptions.

Concise synthesis of strategic imperatives linking clinical advancement, supply resilience, segmentation nuance, and regional variation to operationalize vaccine access goals

In conclusion, the shingles vaccine landscape is at an inflection point where technological advances, demographic shifts, and evolving procurement paradigms intersect to create both challenges and opportunities for stakeholders across the value chain. Recombinant vaccine platforms and improved logistics solutions are raising clinical performance expectations and expanding the scope for broader adult immunization strategies, while tariff and trade dynamics demand more resilient supply chain architectures and adaptive commercial models.

Segmentation nuances across vaccine type, age cohorts, care settings, distribution channels, and dosing formats underscore the importance of tailored approaches that align product attributes with real-world delivery constraints. Regional differences further emphasize the need for customizable engagement models that consider payer structures, infrastructure maturity, and local clinical priorities. Competitive advantage will accrue to organizations that can combine robust evidence generation with operational excellence and flexible contracting to meet the needs of payers, providers, and patients.

Ultimately, proactive planning, strategic collaboration, and investment in both clinical and logistical capabilities will determine which stakeholders are best positioned to improve access and deliver measurable public health impact. This report is intended as a decision-oriented resource to guide such investments and to support evidence-based action across the shingles vaccine ecosystem.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rapid global uptake of recombinant adjuvanted shingles vaccines in adults over 50
  • 5.2. Integration of shingles immunization into routine adult vaccination schedules by national agencies
  • 5.3. Growing investment in next generation herpes zoster vaccine candidates leveraging novel mRNA technology
  • 5.4. Heightened focus on vaccine access programs in emerging markets to close shingles immunization gaps in seniors
  • 5.5. Rising consumer awareness campaigns highlighting long term efficacy and safety profiles of newer shingles vaccines
  • 5.6. Collaborative research partnerships between biotech start ups and big pharma to develop next generation zoster immunogens

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Shingles Vaccine Market, by Vaccine Type

  • 8.1. Recombinant Zoster Vaccine
  • 8.2. Zoster Vaccine Live

9. Shingles Vaccine Market, by Age Group

  • 9.1. 50 To 59 Years
  • 9.2. 60 To 69 Years
  • 9.3. 70 Years And Above

10. Shingles Vaccine Market, by End User

  • 10.1. Clinics
    • 10.1.1. Community Clinics
    • 10.1.2. Private Clinics
  • 10.2. Hospitals
    • 10.2.1. General Hospitals
    • 10.2.2. Specialty Hospitals

11. Shingles Vaccine Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
    • 11.2.1. Digital Pharmacies
    • 11.2.2. E-commerce Platforms
  • 11.3. Retail Pharmacies
    • 11.3.1. Chain Pharmacies
    • 11.3.2. Independent Pharmacies

12. Shingles Vaccine Market, by Dosage

  • 12.1. Multi Dose
  • 12.2. Single Dose

13. Shingles Vaccine Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Shingles Vaccine Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Shingles Vaccine Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. GlaxoSmithKline plc
    • 16.3.2. Merck & Co., Inc.
    • 16.3.3. SK chemicals
    • 16.3.4. GeneOne Life Science
    • 16.3.5. CanSinoBIO
    • 16.3.6. Moderna, Inc.
    • 16.3.7. Chengdu Institute of Biological Products Co., Ltd.
    • 16.3.8. Beijing Institute of Biological Products Co., Ltd.
    • 16.3.9. Yuxi Walvax Biotechnology Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL SHINGLES VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL SHINGLES VACCINE MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL SHINGLES VACCINE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL SHINGLES VACCINE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS SHINGLES VACCINE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL SHINGLES VACCINE MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. SHINGLES VACCINE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. SHINGLES VACCINE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. SHINGLES VACCINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL SHINGLES VACCINE MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL SHINGLES VACCINE MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL SHINGLES VACCINE MARKET SIZE, BY RECOMBINANT ZOSTER VACCINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL SHINGLES VACCINE MARKET SIZE, BY RECOMBINANT ZOSTER VACCINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL SHINGLES VACCINE MARKET SIZE, BY RECOMBINANT ZOSTER VACCINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL SHINGLES VACCINE MARKET SIZE, BY RECOMBINANT ZOSTER VACCINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL SHINGLES VACCINE MARKET SIZE, BY RECOMBINANT ZOSTER VACCINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL SHINGLES VACCINE MARKET SIZE, BY RECOMBINANT ZOSTER VACCINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL SHINGLES VACCINE MARKET SIZE, BY ZOSTER VACCINE LIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL SHINGLES VACCINE MARKET SIZE, BY ZOSTER VACCINE LIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL SHINGLES VACCINE MARKET SIZE, BY ZOSTER VACCINE LIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL SHINGLES VACCINE MARKET SIZE, BY ZOSTER VACCINE LIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL SHINGLES VACCINE MARKET SIZE, BY ZOSTER VACCINE LIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL SHINGLES VACCINE MARKET SIZE, BY ZOSTER VACCINE LIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL SHINGLES VACCINE MARKET SIZE, BY 50 TO 59 YEARS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL SHINGLES VACCINE MARKET SIZE, BY 50 TO 59 YEARS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL SHINGLES VACCINE MARKET SIZE, BY 50 TO 59 YEARS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL SHINGLES VACCINE MARKET SIZE, BY 50 TO 59 YEARS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL SHINGLES VACCINE MARKET SIZE, BY 50 TO 59 YEARS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL SHINGLES VACCINE MARKET SIZE, BY 50 TO 59 YEARS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL SHINGLES VACCINE MARKET SIZE, BY 60 TO 69 YEARS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL SHINGLES VACCINE MARKET SIZE, BY 60 TO 69 YEARS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL SHINGLES VACCINE MARKET SIZE, BY 60 TO 69 YEARS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL SHINGLES VACCINE MARKET SIZE, BY 60 TO 69 YEARS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL SHINGLES VACCINE MARKET SIZE, BY 60 TO 69 YEARS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL SHINGLES VACCINE MARKET SIZE, BY 60 TO 69 YEARS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL SHINGLES VACCINE MARKET SIZE, BY 70 YEARS AND ABOVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL SHINGLES VACCINE MARKET SIZE, BY 70 YEARS AND ABOVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL SHINGLES VACCINE MARKET SIZE, BY 70 YEARS AND ABOVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL SHINGLES VACCINE MARKET SIZE, BY 70 YEARS AND ABOVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL SHINGLES VACCINE MARKET SIZE, BY 70 YEARS AND ABOVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL SHINGLES VACCINE MARKET SIZE, BY 70 YEARS AND ABOVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL SHINGLES VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL SHINGLES VACCINE MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL SHINGLES VACCINE MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL SHINGLES VACCINE MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL SHINGLES VACCINE MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL SHINGLES VACCINE MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL SHINGLES VACCINE MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL SHINGLES VACCINE MARKET SIZE, BY COMMUNITY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL SHINGLES VACCINE MARKET SIZE, BY COMMUNITY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL SHINGLES VACCINE MARKET SIZE, BY COMMUNITY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL SHINGLES VACCINE MARKET SIZE, BY COMMUNITY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL SHINGLES VACCINE MARKET SIZE, BY COMMUNITY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL SHINGLES VACCINE MARKET SIZE, BY COMMUNITY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL SHINGLES VACCINE MARKET SIZE, BY PRIVATE CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL SHINGLES VACCINE MARKET SIZE, BY PRIVATE CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL SHINGLES VACCINE MARKET SIZE, BY PRIVATE CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL SHINGLES VACCINE MARKET SIZE, BY PRIVATE CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL SHINGLES VACCINE MARKET SIZE, BY PRIVATE CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL SHINGLES VACCINE MARKET SIZE, BY PRIVATE CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL SHINGLES VACCINE MARKET SIZE, BY GENERAL HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL SHINGLES VACCINE MARKET SIZE, BY GENERAL HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL SHINGLES VACCINE MARKET SIZE, BY GENERAL HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL SHINGLES VACCINE MARKET SIZE, BY GENERAL HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL SHINGLES VACCINE MARKET SIZE, BY GENERAL HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL SHINGLES VACCINE MARKET SIZE, BY GENERAL HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL SHINGLES VACCINE MARKET SIZE, BY SPECIALTY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL SHINGLES VACCINE MARKET SIZE, BY SPECIALTY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL SHINGLES VACCINE MARKET SIZE, BY SPECIALTY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL SHINGLES VACCINE MARKET SIZE, BY SPECIALTY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL SHINGLES VACCINE MARKET SIZE, BY SPECIALTY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL SHINGLES VACCINE MARKET SIZE, BY SPECIALTY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL SHINGLES VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL SHINGLES VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL SHINGLES VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL SHINGLES VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL SHINGLES VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL SHINGLES VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL SHINGLES VACCINE MARKET SIZE, BY DIGITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL SHINGLES VACCINE MARKET SIZE, BY DIGITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL SHINGLES VACCINE MARKET SIZE, BY DIGITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL SHINGLES VACCINE MARKET SIZE, BY DIGITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL SHINGLES VACCINE MARKET SIZE, BY DIGITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL SHINGLES VACCINE MARKET SIZE, BY DIGITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL SHINGLES VACCINE MARKET SIZE, BY E-COMMERCE PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL SHINGLES VACCINE MARKET SIZE, BY E-COMMERCE PLATFORMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL SHINGLES VACCINE MARKET SIZE, BY E-COMMERCE PLATFORMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL SHINGLES VACCINE MARKET SIZE, BY E-COMMERCE PLATFORMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL SHINGLES VACCINE MARKET SIZE, BY E-COMMERCE PLATFORMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL SHINGLES VACCINE MARKET SIZE, BY E-COMMERCE PLATFORMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL SHINGLES VACCINE MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL SHINGLES VACCINE MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL SHINGLES VACCINE MARKET SIZE, BY CHAIN PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL SHINGLES VACCINE MARKET SIZE, BY CHAIN PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL SHINGLES VACCINE MARKET SIZE, BY CHAIN PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL SHINGLES VACCINE MARKET SIZE, BY CHAIN PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL SHINGLES VACCINE MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL SHINGLES VACCINE MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL SHINGLES VACCINE MARKET SIZE, BY INDEPENDENT PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL SHINGLES VACCINE MARKET SIZE, BY INDEPENDENT PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL SHINGLES VACCINE MARKET SIZE, BY INDEPENDENT PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL SHINGLES VACCINE MARKET SIZE, BY INDEPENDENT PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL SHINGLES VACCINE MARKET SIZE, BY MULTI DOSE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL SHINGLES VACCINE MARKET SIZE, BY MULTI DOSE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL SHINGLES VACCINE MARKET SIZE, BY MULTI DOSE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL SHINGLES VACCINE MARKET SIZE, BY MULTI DOSE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL SHINGLES VACCINE MARKET SIZE, BY MULTI DOSE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL SHINGLES VACCINE MARKET SIZE, BY MULTI DOSE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL SHINGLES VACCINE MARKET SIZE, BY SINGLE DOSE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL SHINGLES VACCINE MARKET SIZE, BY SINGLE DOSE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL SHINGLES VACCINE MARKET SIZE, BY SINGLE DOSE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL SHINGLES VACCINE MARKET SIZE, BY SINGLE DOSE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL SHINGLES VACCINE MARKET SIZE, BY SINGLE DOSE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL SHINGLES VACCINE MARKET SIZE, BY SINGLE DOSE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL SHINGLES VACCINE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL SHINGLES VACCINE MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. AMERICAS SHINGLES VACCINE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 146. AMERICAS SHINGLES VACCINE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 147. AMERICAS SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 148. AMERICAS SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS SHINGLES VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 163. AMERICAS SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2025-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. NORTH AMERICA SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 168. NORTH AMERICA SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. NORTH AMERICA SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 172. NORTH AMERICA SHINGLES VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 174. NORTH AMERICA SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 180. NORTH AMERICA SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 182. NORTH AMERICA SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2024 (USD MILLION)
  • TABLE 184. NORTH AMERICA SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2025-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. LATIN AMERICA SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 188. LATIN AMERICA SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. LATIN AMERICA SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA SHINGLES VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 194. LATIN AMERICA SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 196. LATIN AMERICA SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 198. LATIN AMERICA SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 200. LATIN AMERICA SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 202. LATIN AMERICA SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2024 (USD MILLION)
  • TABLE 204. LATIN AMERICA SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE SHINGLES VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2025-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. MIDDLE EAST SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. MIDDLE EAST SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. MIDDLE EAST SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 252. MIDDLE EAST SHINGLES VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 254. MIDDLE EAST SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 256. MIDDLE EAST SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 258. MIDDLE EAST SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 259. MIDDLE EAST SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 260. MIDDLE EAST SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 261. MIDDLE EAST SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 262. MIDDLE EAST SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2024 (USD MILLION)
  • TABLE 264. MIDDLE EAST SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2025-2032 (USD MILLION)
  • TABLE 265. AFRICA SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. AFRICA SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. AFRICA SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. AFRICA SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 269. AFRICA SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 270. AFRICA SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 271. AFRICA SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 272. AFRICA SHINGLES VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 273. AFRICA SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 274. AFRICA SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 275. AFRICA SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 276. AFRICA SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 277. AFRICA SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 278. AFRICA SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 279. AFRICA SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 280. AFRICA SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 281. AFRICA SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 282. AFRICA SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 283. AFRICA SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2024 (USD MILLION)
  • TABLE 284. AFRICA SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2025-2032 (USD MILLION)
  • TABLE 285. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 286. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 287. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 289. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 290. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 291. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 292. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 293. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 294. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 295. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 296. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 297. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 298. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 299. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 300. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 301. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 302. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 303. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2024 (USD MILLION)
  • TABLE 304. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2025-2032 (USD MILLION)
  • TABLE 305. GLOBAL SHINGLES VACCINE MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 306. GLOBAL SHINGLES VACCINE MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 307. ASEAN SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 308. ASEAN SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 309. ASEAN SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 310. ASEAN SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 311. ASEAN SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 312. ASEAN SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 313. ASEAN SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 314. ASEAN SHINGLES VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 315. ASEAN SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 316. ASEAN SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 317. ASEAN SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 318. ASEAN SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 319. ASEAN SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 320. ASEAN SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 321. ASEAN SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 322. ASEAN SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 323. ASEAN SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 324. ASEAN SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 325. ASEAN SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2024 (USD MILLION)
  • TABLE 326. ASEAN SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2025-2032 (USD MILLION)
  • TABLE 327. GCC SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 328. GCC SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 329. GCC SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 330. GCC SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 331. GCC SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 332. GCC SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 333. GCC SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 334. GCC SHINGLES VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 335. GCC SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 336. GCC SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 337. GCC SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 338. GCC SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 339. GCC SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 340. GCC SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 341. GCC SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 342. GCC SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMAC